Abstract
Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a disease modifying treatment. As increasing evidence has suggested a role for glycogen synthase kinase-3 (GSK-3) in the pathogenesis of the condition we measured total GSK-3 protein (alpha and beta isoforms) and GSK-3 activity (serine 9 phosphorylation) in a group of healthy elderly people, in AD and in mild cognitive impairment (MCI). Total GSK-3 protein was increased in both AD and in MCI without a compensatory decrease in activity. These data suggest that GSK-3 assays might be a useful diagnostic marker in a readily available tissue and moreover that GSK-3 activity is increased in the prodromal phase of the disorder suggesting that inhibition of GSK-3 might be a useful therapeutic strategy.
Original language | English |
---|---|
Pages (from-to) | 1-4 |
Number of pages | 4 |
Journal | Neuroscience Letters |
Volume | 373 |
Issue number | 1 |
DOIs | |
Publication status | Published - 13 Dec 2004 |
Keywords
- Alzheimer’s disease
- glycogen synthase kinase-3
- GCK-3
- biomarker
- lymphocytes
- white cells
- mild cognitive impairment
- MCI